TACI: A novel immune checkpoint in Chronic Lymphocytic Leukemia [ 2018 - 2021 ]

Research Grant

[Cite as]

Researchers: Prof Fabienne Mackay (Principal investigator) ,  Dr Constantine Tam

Brief description Chronic Lymphocytic Leukemia (CLL) is a very common blood cancer. CLL cells actively shut down immune defenses in patients. Moreover, current as well as emerging more targeted therapies suppress immunity and over a quarter of patients will die from an infection despite a good response to cancer treatments. Our laboratory has gained new understanding in the mechanism of action of a new treatment for CLL called Ibrutinib. This information allows us to design improved treatment options for CLL.

Funding Amount $AUD 886,704.46

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]